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The objectives of this thesis were 1) to assess feasibility and practicality of gait performance 
to help differentiate cognitive diagnoses, 2) to assess differences in gait speed and dual-task 
gait cost across the cognitive spectrum, and 3) to determine if poor baseline gait performance 
is associated with future cognitive decline, all within a clinical setting. Patients at the Aging 
Brain and Memory Clinic completed gait assessment, consisting of a usual gait trial and three 
dual-task gait trials, in addition to cognitive and clinical assessments. Patients who had two 
clinic visits during the study period were also included in a longitudinal analysis. Gait speed 
decreased across the cognitive spectrum and was associated with a more severe cognitive 
impairment. Dual-task gait performance on the naming animals condition was also associated 
with future cognitive decline. This thesis presents an investigation of gait performance in a 
clinical setting with a large diverse cohort. 
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Summary for Lay Audience 
This thesis explores the usefulness and feasibility of using a dual-task test, or “walking while 
talking” test, to predict which patients in memory clinics are at higher risk of progressing to 
dementia. In the past, it has been shown that patients with a more pronounced slowdown 
when walking and talking (when compared to just walking) may be more likely to progress 
to dementia, but this test has not been thoroughly studied in a clinic setting. We performed 
this test on patients who were attending the memory clinic at Parkwood Institute for 
evaluation of their memory concerns. We found that this test was feasible to complete, as a 
large majority of patients were able to complete the test. We also found that participants with 
slow walking speed and those who further slowed down when dual-tasking were more likely 
to have been diagnosed with dementia and may be more likely to decline in the following 
years. While we would need a larger study with more participants for each diagnosis and a 
longer follow-up period to better understand this relationship, these results show that dual-
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Key Terms Glossary 
 
Cognition The set of mental activities carried out by the brain that are involved in 
the acquisition, storage, retrieval, and use of information [1]. 
Mobility The ability of a person to complete movement in any form, including 
walking, completing activities of daily living, exercising, and even 
using transportation [2]. 
Neurodegenerative 
diseases 
Diseases that cause progressive damage to a group of neurons and have 
residual cognitive or motor effects (ex. Alzheimer’s Disease, 
Parkinson’s Disease, and amyotrophic lateral sclerosis (ALS)) [3].  
SCI Subjective Cognitive Impairment. A clinical condition characterized by 
subjective cognitive complaints but normal scores on tests of cognition 
[4]. 
MCI Mild Cognitive Impairment. A clinical condition characterized by 
subjective cognitive complaints and lower than normal scores on tests 
of cognition, but without impairments on activities of daily living and 
with absence of dementia [5]. 
Dementia A clinical neurocognitive syndrome caused by multiple underlying 
diseases which cause chronic decline in cognition [6]. Usually 
characterized by objective cognitive impairment which is impacting 
activities of daily living [7,8]. The most common cause is thought to be 
Alzheimer’s disease. 
Gait The pattern of movement of the human body during locomotion [9]. 
Mainly used to describe walking [10]. 
Dual-task gait Walking while performing a cognitively demanding task. 
Dual-task gait speed 
cost 
The amount of slowdown in gait speed due to the added cognitive task, 
expressed as a percent of usual gait speed. 
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Chapter 1  
1 Literature Review 
As the current population is aging, with this comes cognitive impairments and disability, 
of which the most extreme expression is dementia syndromes. Although cognitive 
impairment is not the norm in aging, it is very prevalent among older adults [5]. 
Worldwide, approximately 50 million people are living with dementia, with almost 10 
million new cases each year [11]. There are currently over half a million Canadians living 
with dementia, and this number is expected to grow by 66% in the next ten years [12]. 
However, when an older adult has cognitive complaints, it is difficult to discern in the 
early stages if they are due to the aging process or to dementia syndromes. In the search 
for good biomarkers to detect dementia, those that are easy to perform and clinically 
available will be of extreme importance. In this regard, motor biomarkers and physical 
performance abilities, including gait performance, are emerging as candidates to detect 
those at higher risk of dementia [13]. Recently, it has been postulated that gait 
performance while executing a cognitively demanding task can detect those older adults 
with subtle brain damage and who are more likely to progress to dementia. Therefore, 
this thesis aims to study the association between gait performance, specifically dual-task 
gait testing, and cognitive outcomes for older adults at risk of dementia in a clinical 
setting, with the goal of establishing feasibility of this testing in real clinical scenarios 
and confirm potential predictive abilities. Chapter 1 will provide an overview of 
cognitive impairments, gait testing, and the dual-task paradigm. This chapter will discuss 
the motor-cognitive interface and how it affects mobility in aging. We conclude by 
presenting the study rationale, purpose, and hypotheses. 
1.1 Introduction 
As research into motor biomarkers of cognition has expanded, dual-task gait testing has 
emerged as a “brain stress test” to evaluate the interaction between motor and cognitive 
performance [14]. Dual-task gait testing, defined as “walking while performing a 
cognitively demanding task”, was found to be associated with future dementia in patients 
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with mild cognitive impairment (MCI), a pre-dementia state [15]. As cognitive decline 
varies drastically in these prodromal states, both in timing and in magnitude [5], it is 
important to determine who is at high risk for dementia as early as possible. Research has 
shown that dual-task gait testing may be able to help with this early detection [15], 
however this theory has not been thoroughly studied in a memory clinic setting. 
Demonstrating feasibility and usefulness in a clinical setting would encourage clinicians 
to adopt this testing as part of assessment for memory complaints in older adults. This 
thesis will aim to apply previously described dual-task testing methodologies [14] in a 
large memory clinic cohort, to determine its feasibility and association with various 
cognitive diagnoses. 
1.2 Cognition 
While there are many definitions of cognition, it is usually conceptualized as “the set of 
mental activities involved in the acquisition, storage, retrieval, and use of information” 
[1]. Cognition can be broken down into several functions, including memory, speech and 
language, and executive functions, such as planning and attention, along with many 
others [16]. Several of these cognitive functions will be further explored below as they 
relate to Miyake’s models of cognition [17,18]. This model was chosen this model to 
follow as it has been applied to dual-task research from its earliest days in cognitive 
psychology [19]. 
1.2.1 Executive Function 
Executive function is a higher level cognitive process that produces, regulates, and 
monitors goal-directed behaviours [17,20]. Executive function can be further divided into 
smaller processes, such as volition, planning, shifting between information sets, multi-
tasking, monitoring and updating working memory, and inhibition [17,20]. Executive 
function is commonly linked to the frontal lobe, an anatomical region of the brain which 
has an important role in both cognitive and motor networks [17,21]. Patients with damage 
to the frontal lobe often show detriments in cognitive processes that are part of executive 
function [22]. Earlier research in psychology often referred to executive function tests as 
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“frontal tasks” [17]. However, imaging studies have shown that other regions of the 
brain, mainly in the parietal lobe, are also activated in tasks of executive function [23]. 
 The frontal lobe is sensitive to age related changes in structural integrity [21,24], which 
creates the high prevalence of executive dysfunction in older adults. This is attributed to 
the increase in vascular risk factors often seen in older adults, as these can lead to 
changes and ultimately damage to white matter in the brain [24]. Decline in executive 
function may also precede impairments in memory in both normal aging and in 
neurodegenerative diseases [25]. Impairments in executive function are also highly 
correlated with falls and slow gait speed in older adults [26]. In a large cohort of older 
adults, 35% of patients with low executive function experienced a fall within one year, 
compared to only 15% with higher executive function scores [27]. 
1.2.2 Working Memory 
Working memory is a cognitive function that allows the brain to maintain and retrieve 
task relevant information [18]. In the past, working memory was often confused with 
short term memory. However, there is evidence that the systems function separately, as 
those with short term memory impairments are still able to process information to 
perform activities of daily living [28]. More recently, working memory has been 
associated more with executive function than memory under the model described by 
Miyake [17]. While working memory does require some aspects of information storage, 
the use of working memory is often more the ability to monitor and update information 
during cognitive tasks, which is an important executive function [17]. Working memory 
is also associated with walking, as it is required to follow a route or process changing 
surroundings [29]. In a study of patients with MCI, poor performance on tests of working 
memory was associated with slow usual gait speed and poor performance on dual-task 
gait tests [30]. 
1.2.3 Processing Speed 
Processing speed is the speed at which information is processed during higher level 
cognitive functions associated with executive function [31]. Processing speed peaks in 
adolescence and declines with aging [31]. The processing speed theory of aging 
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described by Salthouse [32] proposes that age related decline in cognition can be 
attributed to decreased processing speed. Under this theory, slow processing speed causes 
decrease in cognitive function in tasks that require time sensitive response and in tasks 
that require input from multiple steps to complete later steps of processing. In relation to 
mobility, some studies suggest slow walking speed may be due to slowing in processing 
speed associated with aging and cognitive decline [33]. An additional study of processing 
speed and gait in older adults found that performance on multiple tests of processing 
speed explained the association between smaller prefrontal area volume and slow gait 
speed [34]. 
1.2.4 Attention 
Attention is described as a number of different processes that are related aspects of how 
the brain becomes receptive to stimuli and how it may begin processing these stimuli 
[35]. While attention has no one definition, it can be thought of as a subprocess of 
executive function [20]. Attention as a process can be separated into focused, sustained, 
and divided or alternating attention [20]. Selective attention, or concentration, is the 
selection of relevant stimuli and the concurrent suppression of irrelevant stimuli [35]. 
Sustained attention is the ability to detect stimuli that are unpredictable over a long period 
of time [36]. Divided attention is the ability to perform more than one task at once, while 
alternating attention is the ability to switch between the two [20,35]. Attentional capacity 
varies between individuals and can be affected by many factors, including fatigue, brain 
injury, and aging [35]. Divided attention is of particular interest, as it is most sensitive to 
changes due to these factors [35] and is representative of the real world condition, as 
individuals are often susceptible to multiple attentional demands. Gait as an isolated task 
in healthy individuals requires limited attentional resources [37,38]. However, in those 
with neurodegenerative or neuromuscular diseases, or when an additional attention 
demanding task is added, attention is needed to maintain postural control and maintain 
steadiness in walking [37,39].  
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1.3 Cognition in Aging 
Observed decline in cognition with aging can be attributed to slower processing speed 
[32] and depletion of cognitive reserve [40]. Decreased processing speed leads to 
cognitive operations not being completed within the required time limit for response. It 
can also cause breakdown in simultaneous cognitive operations due to products from 
earlier steps being forgotten once later steps are completed [32]. Alternatively, cognitive 
reserve is the idea that how different individuals process tasks makes some more resistant 
to deficits due to brain pathology [40]. The cognitive reserve theory of decline postulates 
that individuals have different levels of processing capacity, but all have a critical 
threshold and once one’s capacity declines below this level, clinical and functional 
impairments are seen [40]. However, these impairments present differently in different 
people, which leads to the differential diagnoses of cognitive impairments seen in clinical 
settings. 
1.3.1 Spectrum of Cognitive Impairment 
There are many diagnoses associated with cognitive impairment that are seen with aging, 
but three of these are commonly used in clinical practice. In order of increasing severity, 
they are subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and 
dementia (see Figure 1.1). SCI, also called subjective cognitive decline (SCD) [4], is 
characterized by the presence of memory complaints or worry about decline in cognition 
(e.g. slowness and word finding difficulties), with no objective impairment on cognitive 
testing (normal for their age and education level). While these patients do not have 
objective cognitive impairments, they are still at heightened risk of future cognitive 





Figure 1.1 Model of the course of cognitive decline in relation to progression of 
Alzheimer's Disease pathology. Republished with permission of Annual Reviews, 
from Rabin, Smart, & Amariglio (2017) [4]; permission conveyed through 
Copyright Clearance Center, Inc. 
 
1.3.2 Mild Cognitive Impairment 
MCI is described in the literature as a pre-dementia state, as it is characterized by both 
subjective memory complaints and objective decline on cognitive testing greater than 
expected for normal aging [42]. To be diagnosed as MCI, patients must not have deficits 
in their activities of daily living due to their changes in cognition, but they are at higher 
risk for converting to dementia [42]. It is estimated that 10-20% of older adults over the 
age of 65 meet these criteria for MCI [5]. While 5-15% of those with MCI may progress 
to dementia each year, up to 30% of those with MCI will remain stable or revert back to 
normal cognition [5,43]. MCI may present in many different cognitive domains, and 
decline in each domain may present differently throughout the course of MCI [44]. In 
general, MCI that affects any memory domains is termed amnestic MCI, while non-
amnestic MCI affects other domains of cognition, usually including attention, executive 
function, language or visuospatial skills [45]. MCI may also be present in more than one 
domain (multi-domain MCI) or a single domain. While memory is the most commonly 
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cited domain to have impairment in MCI, impairments of executive function are the 
second most prevalent [5,46] and may also be associated with increased depression and 
anxiety in patients with MCI[47]. 
1.3.3 Dementia 
Dementia is a clinical syndrome resulting from several different underlying diseases 
which cause chronic impairment in cognition [6]. Dementia diagnosis is also 
characterized by subjective cognitive impairment, usually memory complaints with an 
objective impairment on cognitive testing greater than expected for normal aging, both 
affecting the patient’s activities of daily living [8,48]. The four major types of dementia 
are Alzheimer’s Disease, Lewy Body Disease, Frontotemporal dementia, and vascular 
dementia [49]. Alzheimer’s disease dementia is the most common of these and accounts 
for 60-80% of total cases of dementia [50]. Five hundred sixty-four thousand Canadians 
are currently living with dementia, which costs the Canadian healthcare system $10.4 
billion annually [51]. In 2018, Alzheimer’s disease was the eighth highest overall cause 
of death in Canada and the sixth highest for those aged 85 and older [52].  
Currently, treatment options for dementia are limited.  Pharmacological treatments are 
aimed mainly at treating symptoms of the diseases, not the diseases themselves, and may 
come with physical and neuropsychiatric side effects [53]. Many multi-domain treatment 
studies including lifestyle interventions have shown promise in improving cognition in 
patients with dementia, however these may have issues of adherence and often require 
healthy lifestyle adaptation throughout the entire lifespan to show maximum benefits 
[54]. Therefore, the search for in depth knowledge on the causes of dementia and 
methods of early detection and diagnosis has become of the utmost importance in 
research [55]. 
1.4 Gait 
Gait can be defined as “the pattern of movement of the human body during locomotion” 
[9]. Gait is commonly used to describe the manner or style of one’s walking [10], and is 
one key component of overall mobility [56]. While there are normal fluctuations in gait 
parameters, gait is generally stable between each stride even in changing external 
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environments [57]. However, gait abnormalities are highly prevalent in older adults, both 
in those with neurologic diseases and healthy older individuals [58]. Population based 
studies estimate 30% of older adults over 60 have a gait disorder, but this may increase to 
up to 60% for those over 80 years old [59,60]. Gait disturbances, known as a deviation 
from a normal gait pattern, may be either continuous, when caused by an underlying 
neuromuscular condition, or episodic, when in response to a change in the environment 
[61]. Increased gait variability, or step-to step fluctuations in time or distance, may be 
either of these, as it can be due to many conditions, such as stroke, neuropathy and 
depression, or due to environmental changes, such as negotiating an obstacle or 
performing multiple tasks at once [62]. Gait disturbances, and specifically high gait 
variability, have been associated with future risk of falls [63–66], frailty [67], mobility 
impairments and disability [68–70], and cognitive impairments and dementia [15,71–74]. 
1.4.1 Gait Cycle 
The gait cycle is made up of both stance and swing phases (see Figure 1.2), with the 
stance phase marking when the foot is on the ground, and the swing phase marking when 
the foot is moving through the air [10,75]. The stance phase comprises about 60% of the 
gait cycle, and begins and ends with both feet on the ground [76]. The swing phase makes 
up the other 40% of the cycle, and begins with toe-off and ends with heel strike [76]. 
Once full gait cycle, or stride, is the interval between when one foot strikes the ground 




Figure 1.2 Phases of the gait cycle. From Kharb et al. (2011) [75] 
1.4.2 Gait Assessment 
Gait can be assessed by simple clinical observation or by quantitative testing. 
Quantitative gait testing can be done using various technologies, such as video 
recordings, electronic walkway, or accelerometer and wearable sensors. Gait testing 
technologies can give extended information about a person’s walking and defined spatio-
temporal quantitative variables can be assessed and recorded (see Table 1.1). For 
example, computerized walkways using pressure sensors to detect each footprint have 
become popular in research as they do not require a trained clinician and are highly 
reliable [77,78]. However, these technologies may be too expensive and the outputs too 
complex for use in clinical settings. 
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Alternatively, clinical observation of gait has some benefits as well. Clinical observation 
of gait includes an individual performing a number of walks while a trained clinician 
observes one or more parameters of the individuals gait pattern. These parameters may 
include: initiation, posture, gait speed/velocity, arm swing, freezing and more [76]. 
During clinical observation of gait, one important and clinically relevant quantitative 
variable, gait speed, can simply be assessed using a stop watch and a marked path of a 
known distance [14]. Using our previously published guidelines [14], gait testing can be 
done in a clinical setting using a measured path on the floor (ideally six meters) and a 
stop watch. While clinical observation of gait gives less quantitative information overall, 
it can give clinicians useful information and it has been validated against traditional 
technologies [79]. However, this approach may require more nuanced training for 
assessment and classification of results. 
Table 1.1 Definitions of Commonly Used Quantitative Spatiotemporal Gait 












1.4.3 Gait Speed 
Gait speed can be defined as “the distance covered by the time to ambulate”, and is a 
simple to collect but effective measure of mobility [14,80]. It can be measured using 
either quantitative gait testing technologies, or the simple stop watch collection method 
as described above. Gait speed has been described as the sixth vital sign in older adults 
due to its sensitivity to detecting changes in different settings and clinical conditions [81–
83]. It was found that a decrease in gait speed of 0.1m/s was associated with poorer 
health status and disability, while an increase of the same amount of associated with 
overall well-being [82]. Gait speed has also been called the functional vital sign due to its 
predictive abilities and ease of collection [83]. The term “bradypedia” has even been 
suggested as a clinical diagnosis for slow gait speed [84]. 
Slow gait speed has also been associated with falls, limitations in activities of daily 
living, dementia  and even mortality [65,81,85–88]. In a pooled analysis of several large 
cohort studies (n=27,220), a difference of 0.1m/s faster in gait speed was associated with 
a decrease in risk of mobility disability by 26% in men and 27% in women (see Figure 
1.3), and a decrease in risk of mortality over four years between 18% and 24% [89]. 
These associations between slow gait speed and poor cognitive function can already be 
seen in midlife, and may even be related to poor development in childhood [90,91]. 
However, accelerated decline in gait speed in aging has been associated with an increase 
in energy demands of walking, specifically due to changes in body composition, lower 
extremity pain, poor balance, and other biomechanical and neuromuscular factors 
[92,93].  
While usual or self-selected gait speed is the most commonly studied, other 
measurements of gait speed may be of interest. Maximum walking speed, where the 
participant walks as fast as they can without running, has been suggested as a useful 
measure in detecting changes in mobility performance and is associated with mobility 
disability [14,83,94]. Additionally, gait speed while performing an added cognitive task, 
or dual-task gait speed, has been associated with cognitive impairments and future risk of 
cognitive decline [15,95,96]. 
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Changes in gait speed may be one of the earliest physical symptoms of dementia and are 
associated with severity of the disease [97]. Therefore, tests of gait and motor 
performance may be useful in detecting early signs of cognitive impairment, before 
cognitive symptoms are detectable [98]. 
 
Figure 1.3 Gait speed in association with mobility difficulty for men (A) and women 
(B). Used with permission of Oxford University Press, from Perera et al. (2016) [89] 
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1.4.4 Gait and Cognition 
While gait was once thought to be an automatic process requiring little cognitive input, 
recent evidence has shown that gait and cognition may be more highly correlated than 
once thought [38]. Firstly, gait performance and cognition both decline with age, and 
large cohort studies have shown they often coexist in older adults [63,99–101]. Poor gait 
performance has specifically been associated with low performance on tests of executive 
function, as this higher level cognitive process collects information from the sensory 
systems and uses it to produce and monitor behaviour and movements [20]. Gait 
performance, particularly speed, has also been linked to other cognitive domains, such as 
memory [102] and attention [39]. Additionally, decreased gait speed is one of the earliest 
physical symptoms of dementia and may manifest years before cognitive impairments are 
detectable [97]. 
1.5 Motor-Cognitive Interface 
The presented evidence linking gait and cognition creates the theory of a motor-cognitive 
interface (see Figure 1.4). This relationship between mobility and cognitive domains is 
not fully understood yet [62], but it is known that regulation and control of gait and 
cognitive processes rely on shared brain areas and networks that are susceptible to 
damage during  aging, diseases associated with aging, and neuropathology. Completing 
both a motor and cognitive task at once can put stress on these systems and even overload 
them if there are already cognitive challenges present. This overload can lead to deficits 
in one or both tasks that can be measured, and provides an opportunity to use a dual-task 




Figure 1.4 (A) Traditional view of cognitive and gait decline with aging and (B) the 
emerging view based on evidence of the cognitive-motor interface. From Montero-
Odasso et al. (2012) [63] 
1.5.1 Dual-Task Paradigm in Gait and Cognition Assessment 
The dual-task paradigm suggests that two tasks done at the same time creates competition 
between the two tasks for a limited amount of brain resources, and this competition 
creates a detriment in one or more of the activities [20]. Dual-task gait testing, defined as 
“walking while performing a cognitively demanding task”, applies this paradigm to the 
interaction of mobility and cognition. Walking and cognitive tasks rely on shared 
networks in the brain, and while these shared networks are also not fully known, the most 
commonly described areas include the frontal lobe (ex. prefrontal and supplementary 
motor areas) and temporal lobe (ex. hippocampus) [103–105]. This testing was derived 
from a seminal study showing that nursing home residents who were not able to hold a 
conversation while walking were at a higher risk of falls [106].  
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1.5.2 Theories of Dual-Tasking 
There are three main theories for how dual-tasking is processed in the brain. The first of 
these is the capacity sharing model, which is based on the idea that attentional tasks 
performed at the same time compete for a limited capacity of neural resources 
[39,107,108]. The competing tasks can overload these resources, therefore causing the 
disturbances we see in gait and cognitive tasks while dual-tasking [20]. The degree of this 
effect, and in which of the two tasks it shows up in, is dependent on the type and 
difficulty of both the cognitive task and the walking task [39,108]. The instructions given 
can also influence which task is given priority (ie. higher attentional resource allocation) 
[107], which is why in dual-task gait testing it is suggested to instruct participants to 
equally prioritize both tasks [14] in order to best mimic what happens naturally while 
walking [109,110]. 
A second theory of the processing of dual-tasking is the bottleneck theory, which 
proposes that if two tasks require the same processor and that processor can only process 
one task at a time, the second task is put on hold until the first is completed [107,108]. It 
is also possible that multiple bottlenecks occur during the entire response process at 
different stages, such as response selection and response execution [107,108]. 
Finally, a third theory of dual-tasking has to do with the similarities and differences 
between the two tasks, and is called the cross-talk theory [108,111]. This theory relates to 
decreasing peripheral overload, and postulates that similar tasks are more easily 
processed together due to the “turning on” and use of similar processors [108]. For 
example, it was found that performance in a rhythmic cognitive task, counting backwards 
by ones, could be improved while walking when compared to just sitting, as walking also 
has a rhythmic component [112]. However, there is some criticism of this theory that 
suggests similar tasks processed together may cause side effects or “confusion” that 
negatively affect performance [108]. 
1.5.3 Dual-Task Gait Cost 
From dual-task gait testing we can calculate dual-task gait cost (DTGC), which is a 
measure of the “cost” incurred by dual-tasking versus doing either the mobility or 
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cognitive task alone (see Figure 1.5). DTGC measures how the added cognitive task 
impairs gait performance, and can be calculated with any of the quantitative variables 
collected in gait testing [14]. Dual-task cognitive cost (DTCC) can also be calculated, 
depending on the cognitive task being completed, using response rate, number of correct 
answers, or reaction time [14]. Older adults may prioritize gait and balance over 
cognitive tasks [113], which cause DTCC to be larger than DTGC. However, DTGC for 
gait speed is the more commonly reported measure of dual-task gait testing, without 
consideration of DTCC, possibly due to differences in calculation of DTCC based on 
type of cognitive task used and the difficulty of determining an accurate rate of 
enumeration for the cognitive task, both by itself and while walking [114]. 
 
 
Figure 1.5 Visual representation of the dual-task cost calculation for gait speed. 
Unpublished, used with permission from Dr. Manuel Montero-Odasso. 
 
1.5.4 Studies of Dual-Task Gait Testing in a Clinical Setting and Current 
Gaps in the Literature 
To date, there are only three published studies of dual-task gait testing in a memory clinic 
setting that we are aware of. The first of these was by MacAulay and colleagues [115], 
which found patients with MCI made more cognitive errors while dual-tasking and 
slowed down more when dual-tasking, in comparison to just walking, than healthy 
controls (this was not quantified as dual-task cost but represents the same phenomenon). 
Another study by Nielsen and colleagues [96] showed that dual-task cost using the Timed 
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Up and Go test was able to separate healthy controls from patients with MCI and from 
patients with dementia patients, but that it had a low prognostic value for future cognitive 
decline. Furthermore, both of these studies had small sample sizes (n=61 and 86, 
respectively), and these studies did not examine patients with a diagnosis of SCI. The 
final study available was published by our group [116], and is a preliminary analysis of 
the results that will be presented in this thesis. However, this previously published work 
only included cross-sectional data and about half of the sample that will be presented 
within this thesis. This previously published work concluded that using the three main 
cognitive subtypes: SCI, MCI, and dementia, patients diagnosed with dementia had 
slower gait speed and higher dual-task cost. 
1.6 Overview of Thesis 
1.6.1 Rationale 
The presented literature supports the potential use of dual-task gait testing as a “stress-
test” on the brain and its allocation of resources, which may be useful for detecting those 
individuals at high-risk for future cognitive decline. Specifically, dual-task gait 
performance was associated with progression to dementia in patients with MCI [15]. 
However, with only two relatively small studies of dual-task gait testing in clinical 
settings [95,96], there exists a gap in the literature of a large, long-term clinical cohort 
with a wider spectrum of cognitive diagnoses who are tested under multiple different 
dual-tasks. 
1.6.2 Purpose 
The purpose of this thesis is to, within a clinical setting, 1) assess feasibility and 
practicality of gait performance to help differentiate cognitive diagnoses, 2) assess 
differences in gait speed and dual-task gait cost across the cognitive spectrum, and 3) 
determine if poor gait performance at baseline is associated with future cognitive decline. 
1.6.3 Hypotheses 
At the cross-sectional level, it was hypothesized that 1) gait speed will be slower and 
dual-task gait cost will be higher for older adults attending a memory clinic that are 
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diagnosed with more severe cognitive impairment and 2) poorer performance on the dual-
task gait assessment will be predictive of worse cognitive impairment. 
Within the longitudinal sub-study, it was hypothesized that slow gait speed and higher 




Chapter 2  
2 Methods 
We have previously published a sub-set of this data in the Journal of Alzheimer’s Disease 
and the following methods have been adapted from this publication [116]. 
2.1 Study Design and Participants 
Clinic-based study that included all consecutive older adults who were assessed for 
memory complaints at the Aging Brain and Memory Clinic at Parkwood Institute in 
London, Ontario, Canada between July 2015 and May 2019. In order to be included in 
the current study, participants had to (1) be over 50 years of age, (2) be able to safely 
ambulate six meters without an assistive device, and (3) be fluent in English and able to 
understand test instructions. In order to be included in longitudinal analysis, participants 
had to meet baseline inclusion criteria and have a second visit in the clinic minimum of 
twelve months after their first visit. Follow-up visits in the clinic were usually scheduled 
two to three years after the baseline visit. To maximize inclusion and to ensure an 
accurate representation of the population seen in our clinics, no additional exclusion 
criteria were used. Participants were grouped into three categories based on final 
diagnosis: SCI, MCI and dementia. Diagnosis was achieved using a consensus 
conference and established criteria (Petersen criteria for MCI [5] and the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition revised (DSM IV-TR) criteria for 
dementia [8]) after assessment performed by a geriatrician specialized in cognitive aging 
and dementia. Petersen criteria for MCI was ascertained by satisfying the following four 
criteria i) subjective cognitive complaints; ii) objective cognitive impairment in at least 
one of the following cognitive domains: memory, executive function, attention, and 
language; iii) preserved activities of daily living; confirmed by a geriatrician specialized 
in cognitive aging and dementia; iv) absence of dementia using criteria from the DSM 
IV-TR. This study was approved by the Health Science Research Ethics Board at 
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Western University and the Clinical Research Impact Committee at Lawson Health 
Research Institute, both in London, Ontario, Canada.  
2.2 Demographic and Clinical Variables 
All participant information and gait testing results were collected from patient charts. 
Demographic and clinical information collected included age, sex, falls history in the past 
12 months, years of education, medications and comorbidities (see Appendix B). 
Comorbidities were measured as total number of “yes” responses on a clinical 
comorbidities checklist. Cognitive variables include Mini Mental State Examination 
(MMSE) score and the Montreal Cognitive Assessment (MoCA) score. 
2.3 Gait Testing Procedure  
All gait assessments were performed at the start of the clinical visit in a hallway outside 
the clinic room using a six-meter path. Six meters was chosen as it has been shown to be 
an appropriate length to be used for older adults without mobility impairments to ensure 
steady state walking is achieved [117]. Lines were marked on the floor to determine the 
stop and start points. One meter was added to each end of the pathway (as shown in 
Figure 2.1) to ensure acceleration and deceleration phases were not recorded. Walking 
trials were timed using a handheld stopwatch and recorded to two decimal places. Speed 
was calculated by dividing the known distance by the time spent walking from start to 
end points marked on the floor, in each trial, for each participant, and then converted to 
cm/s.  
All participants were asked to complete a total of four walk trials. The first trial was 
always the preferred or usual gait speed trial. For this trial, the participants were asked to 
walk at their normal, every-day walking speed. The next three trials were the dual-task 
walking trials, which comprised walking at usual speed while preforming an added 
cognitively demanding task. The order of dual-task trials was fully randomized. The three 
tasks used for this study were counting backwards by 1’s from 100 out loud, naming 
animals out loud, and counting backwards by 7’s from 100 out loud, which have been 
previously validated and are listed here in order of increasing cognitive demand [37,118–
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120]. Participants were instructed to equally prioritize both walking and the cognitive 
task to accurately replicate normal daily activities[20,109]. Number of enumerations and 
errors per each dual-task trial was also recorded in the patient’s chart along with the 
speed for each trial. Participants were included in the analysis as long as they completed 
the usual gait speed trial and at least one of the dual-task trials. This gait protocol 
followed the Canadian guidelines for gait assessment we have published [14]. 
 
Figure 2.1 View of the gait testing pathway used in the Aging Brain and Memory 
Clinic. From Cullen et al. (2018) [14] 
2.4 Feasibility Measures 
For cross-sectional feasibility investigations, both quantitative and qualitative measures 
were used. Participant agreement was measured quantitatively as the percentage of 
eligible participants who completed a gait assessment at the clinic visit. Participants were 
included if they completed the usual gait walk and at least one dual-task walk. In order to 
establish the feasibility and practicality of gait testing in a busy clinical setting, after the 
study was completed we surveyed the two primary assessors who completed the gait 
testing. Assessor satisfaction was measured using the following questions: 
Using a Likert scale from 1 (‘Very Easy’) to 5 (‘Very Hard’):  
1) How easy was the dual-task gait assessment to complete? 
22 
 
2) How easily was the dual-task gait assessment integrated into the flow and timing of the 
clinic appointment? 
There was also the option to add additional comments to any of the ratings given above. 
2.5 Calculation of Dual-Task Gait Cost (DTC) 
DTC was calculated for each dual-task trial using the appropriate velocities. DTC was 
calculated in Microsoft Excel 2010 using the following formula: DTC = [(usual gait 
speed – dual-task gait speed)/usual gait speed] x 100. DTC is expressed as a percentage 
of slowing from the usual gait speed as a result of the added cognitive task [121]. For this 
thesis, DTC will refer only to dual-task gait cost, as dual-task cognitive cost was not 
examined. 
2.6 Outcome Variables and Criteria 
Following the objective of this thesis to determine if poor baseline gait performance was 
associated with future cognitive decline, three outcome variables were used to quantify 
cognitive decline at the follow-up visit. The first of these was a progression to a more 
severe diagnosis of cognitive impairment, which was categorized as conversion from SCI 
to MCI or dementia, MCI to dementia, or early/prodromal dementia to moderate or 
severe dementia. While this outcome is important for clinical use and for comparison to 
other studies measuring conversion to dementia [15,71], there is an inherent 
heterogeneity in these various changes and the potential for subjective bias. For example, 
conversion from MCI to dementia, based on some criteria, can be a result of the patient 
themselves or their caregiver reporting a change in activities of daily living (ADLs) and 
not due to changes in cognition [122–124]. For this reason, we have also decided to 
investigate if gait performance predicts decline in scores on cognitive tests, specifically 
the Mini Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA). 
These objective measures have been thoroughly studied, and it was determined based on 
previous studies that cognitive decline would be operationalized as a drop of greater than 
two points per year on the MoCA [72,125]. For example, it was previously found in a 
study of MCI patients that the mean drop in total MoCA score was 2.19 points per year in 
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those who eventually converted to dementia and 1.72 points per year for those who 
remained MCI [125]. Estimates of average rate of decline on the MMSE vary and have 
been reported between less than one point per year for older people with normal 
cognition [126] and up to and over four points per year for patients with dementia [127–
129]. Given the mixed diagnosis groups in our sample and to remain consistent with our 
criteria for MoCA decline, this outcome variable was also operationalized as a drop of 
greater than two points per year. Given the average follow-up period in our sample is at 
least two years, these values are also consistent with the minimal detectable change of 
three points on the MMSE and four points on the MoCA [130].  
2.7 Statistical Analyses 
Data were checked for normality and homogeneity of variances using the Kolmogorov-
Smirnov and Levene’s tests, respectively. Demographic and clinical characteristics were 
summarized as means and standard deviations or frequencies and percentages, as 
appropriate. Baseline demographic characteristics were compared between groups using 
one-way analysis of variance (ANOVA) or Chi-Square tests. Statistical significance was 
set at p<0.05. Statistical analyses were conducted using SPSS, version 25 (IBM 
Corporation). 
2.7.1 Cross-sectional Analyses 
Gait speed and dual-task gait cost were compared across groups using a repeated 
measures two-way analysis of variance (ANOVA), both unadjusted and adjusted for age, 
to evaluate the effect of cognitive diagnosis (diagnosis) across the different gait tasks 
(task) and their interaction (diagnosis x task). 
The association between gait performance and diagnosis of an objective cognitive 
impairment MCI or dementia) was analyzed using a multi-factor regression with SCI as 
the reference category, with gait speed and dual-task cost as the independent variables 
and adjusted for age and sex. The association between gait performance and dementia 
diagnosis was also analyzed using a logistic regression, with dementia and pre-dementia 
(SCI or MCI) as the dichotomous outcome variable. 
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Receiver Operating Curves (ROC curves) with corresponding area under the curve 
(AUC) were created to determine the optimal cut-off point for slow gait speed in each 
gait test. AUC was classified using the clinical categorizations of low accuracy (0.5-0.7), 
moderate accuracy (0.7-0.9) and high accuracy (0.9 and higher). Moderate accuracy (0.7 
or higher) is considered clinically relevant [131]. Sensitivity and specificity were 
determined for each cut-off point from these curves. Association between dementia 
diagnosis and slow gait speed using these cut-off points was assessed using a binary 
logistic regression. 
2.7.2 Longitudinal Analyses 
Cox regression analyses were completed to assess risk of progressing to a worse 
diagnosis, as measured by hazards ratios (HR), based on gait performance (usual and 
dual-task gait speed and dual-task cost) as continuous and dichotomous variables. Cut-off 
values for gait speed and dual-task cost were set at the mean of each variable for the 
sample. Proportional hazards were checked using visual inspection of Kaplan-Meier 
curves. Time was calculated as the number of months between the baseline visit and the 
follow-up visit in the clinic. To account for different follow-up periods, decline on 




Chapter 3  
3 Cross-Sectional Gait Performance and Measurement in a 
Clinical Setting 
This chapter will explore the use of gait testing in a memory clinic setting from a cross-
sectional standpoint. Specifically, this chapter will focus on the previously stated goals of 
this thesis, to determine 1) differences in gait speed and dual-task gait cost across the 
cognitive spectrum in a clinical setting and 2) if measuring gait performance is feasible in 
a clinic setting and useful to help differentiate cognitive diagnoses. 
3.1 Results 
3.1.1 Participant Characteristics 
Three hundred seventy-two participants (mean age 72.83 ± 10.05 years; 50.8% female) 
met inclusion criteria. This sample included eighty-one participants with SCI, one 
hundred fifty-five participants with MCI and one hundred thirty-six with dementia. 
Characteristics of the study sample stratified by cognitive diagnosis are presented in 
Table 3.1. Mean age of participants was significantly higher across the spectrum of 
cognitive impairment. As expected, MMSE and MoCA scores were significantly lower in 
groups with more severe cognitive impairment diagnosis. The SCI group had 
significantly higher years of education than both the MCI and dementia groups. All three 
groups had similar number of comorbidities, number of medications, and twelve month 







Table 3.1 Demographic and clinical characteristics of study participants in sample 
stratified by cognitive diagnosis 
  Stratified by Cognitive Diagnosis  









Age (mean, SD) 72.83 (10.05) 65.57 (10.38) 71.97 (9.30) 78.13 (7.38) <0.001 
Female (n, %) 189 (50.8%) 47 (58.0%) 75 (48.4%) 69 (50.7%) 0.281 
Years of education 
(mean, SD) 




5.7 (3.3) 5.6 (3.7) 5.9 (3.2) 5.5 (3.1) 0.636 
No. of medications 
(mean, SD) 
7.9 (4.5) 8.0 (5.0) 7.8 (4.3) 8.0 (4.3) 0.921 
MMSE score 
(mean, SD) 
25.4 (4.6)f 29.0 (1.6) 26.6 (2.8)g 21.8 (4.9) <0.001a 
MoCA score 
(mean, SD) 
21.1 (5.0)h 26.8 (2.0)i 21.1 (3.6)j 16.8 (4.0)k <0.001a 
Falls (n, %)l      
     No falls 276 (74.2%) 63 (77.8%) 119 (76.8%) 94 (69.1%) 0.230 
     1 fall 59 (15.9%) 14 (17.3%) 22 (14.2%) 23 (16.9%)  
     2+ falls 37 (9.9.1%) 4 (4.9%) 14 (9.0%) 19 (14.0%)  
Statistically significant values are bolded. 
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment. 
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.  
a, p-value reported from Welch’s Test for unequal variance. 
b, data available for n=332. 
c, data available for n=74. 
d, data available for n=143. 
e, data available for n=115. 
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f, data available for n=370. 
g, data available for n=153. 
h, data available for n=339. 
i, data available for n=80. 
j, data available for n=152. 
k, data available for n=107. 

















3.1.2 Differences in Gait Speed Across the Diagnosis Groups 
Gait speed for each group in each gait condition is summarized in Figure 3.1, Figure 3.2, 
and Table 3.2. Gait speed was lower in each group from usual gait to dual-tasking and 
with increasing dual-task difficulty. The repeated-measures ANOVA was significant 
when unadjusted and adjusted for age. Post-hoc analysis revealed that in the usual gait, 
counting backwards and naming animals tasks, the SCI and MCI groups were statistically 
similar to each other, but the dementia group was significantly different from both of 
those groups. In the serial sevens condition, only the SCI and dementia groups were 
statistically different (p=0.01). Within groups analysis showed that in the SCI and 
dementia groups the counting backwards and naming animals tasks were statistically 
similar (p=0.07 and p=0.31, respectively). All other within groups comparisons were 


















































































79.26 (21.04) 65.79 (22.11) 




65.14 (19.77) 55.61 (20.25) 
Statistically significant values are bolded. 
n=76 excluded due to missing data in one or more gait conditions.  
Model 1: Unadjusted. Model 2: Adjusted for age. 
p-values reported are using the Greenhouse-Geisser correction for sphericity.  
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3.1.3 Differences in Dual-Task Gait Cost (DTC) Across the Diagnosis 
Groups 
DTC for each group is summarized in Figure 3.3, Figure 3.4, and Table 3.3. The repeated 
measures ANOVA showed that DTC performance was only significantly associated with 
which dual-task condition was being performed (p<0.001). Within each diagnosis group, 
DTC increased with increasing task difficulty. There was no statistically significant 
difference in DTC between diagnosis groups (p=0.43). 
 
 











































25.21 (15.65) 23.26 (24.95) 24.95 (14.72) 27.14 (16.81) 
Serial sevens 38.13 (17.39) 37.60 (18.41) 38.41 (17.32) 38.18 (16.86) 
Statistically significant values are bolded. 
n=76 excluded due to missing data in one or more gait conditions.  
Model 1: Unadjusted. Model 2: Adjusted for age. 
p-values reported are using the Greenhouse-Geisser correction for sphericity.  
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3.1.4 Association between Gait Performance and Objective Cognitive 
Impairments 
The association between gait performance on each dual-task condition and cognitive 
diagnosis was examined with SCI as the reference level (Table 3.4). For all gait 
conditions, MCI and SCI were statistically similar, except for gait speed in the naming 
animals condition, where slower speed was associated with an MCI diagnosis (presented 
as 1/exp(B): OR=1.01; 95% CI=1.00-1.02; p= 0.048). In contrast, poor performance 
(slower speed and higher DTC) was associated with diagnosis of dementia in almost all 
gait conditions. The exception to this was dual-task cost in the serial sevens condition, 
which was not associated with higher risk of dementia diagnosis (OR=1.01; CI=0.99-














Table 3.4 Association between gait performance and cognitive impairment (MCI or 
Dementia) vs subjective impairment (SCI) 
Gait Condition Odds Ratio (95% CI) p-value 
Usual gait speed 
  
          MCI 1.00 (0.99-1.01) 0.66 
          Dementia 1.02 (1.01-1.04) 0.001 
Counting backwards 
  
     Speed 
  
          MCI 1.01 (1.00-1.02) 0.16 
          Dementia 1.05 (1.03-1.06) <0.001 
     Dual-Task Gait Cost 
  
          MCI 1.01 (0.99-1.03) 0.25 
          Dementia 1.04 (1.02-1.06) <0.001 
Naming animals 
  
     Speed 
  
          MCI 1.01 (1.00-1.02) 0.048 
          Dementia 1.04 (1.02-1.06) <0.001 
     Dual-Task Gait Cost 
  
          MCI 1.02 (1.00-1.03) 0.09 
          Dementia 1.03 (1.01-1.05) 0.001 
Serial sevens 
  
     Speed 
  
          MCI 1.01 (0.99-1.02) 0.42 
          Dementia 1.03 (1.01-1.04) 0.004 
     Dual-Task Gait Cost 
  
          MCI 1.01 (0.99-1.02) 0.51 
          Dementia 1.01 (0.99-1.03) 0.46 
Statistically significant values are bolded. 
SCI is the reference category. 
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Adjusted for age and sex. 










































3.1.5 Association between Gait Performance and Dementia Diagnosis 
Based on the previous results, the association with gait performance was also compared 
between dementia and the pre-dementia states (SCI and MCI) (Table 3.5). Again, slower 
gait speed and higher dual-task cost were significantly associated with dementia 
diagnosis in all gait conditions, except for dual-task cost in the serial sevens condition 


















Table 3.5 Association between gait performance and dementia diagnosis 
Gait Condition Odds Ratio (95% CI) p-value 
Usual gait 
  
     Speed 1.02 (1.01-1.03) <.001 
Counting backwards 
  
     Speed 1.04 (1.02-1.05) <.001 
     Dual-task gait cost 1.03 (1.02-1.05) <.001 
Naming animals 
  
     Speed 1.03 (1.02-1.04) <.001 
     Dual-task gait cost 1.02 (1.01-1.04) 0.004 
Serial sevens 
  
     Speed 1.02 (1.01-1.04) 0.003 
     Dual-task gait cost 1.00 (1.00-1.02) 0.675 
Statistically significant values are bolded. 
Adjusted for age and sex.  








3.1.6 Optimal Cut-off Values for Gait Speed 
ROC Curve analysis showed a moderate ability to separate dementia patients from pre-
dementia diagnoses for all gait conditions (Figure 3.5 and Table 3.6). While the AUC for 
each of the four gait tests were all statistically significant (p<0.001), only the counting 
backwards condition had moderate accuracy (AUC=0.711). The naming animals 
(AUC=0.698) and usual gait (AUC=0.693) conditions had low accuracy just below the 
moderate accuracy cut-off (AUC > 0.7). The optimal cut-off points for each gait test were 
as follows: 99.18 cm/s for usual gait, 80.54 cm/s for counting backwards, 82.72 cm/s for 
naming animals and 71.85 cm/s for serial sevens. These all gave moderate sensitivity 
(62.8%-72.3%) and specificity (60.0%-64.9%).  
Using these cut-off values, a dichotomous gait variable was created (slow or fast gait 
speed). Binary logistic regression showed that slow gait speed was significantly 
associated with dementia diagnosis in all gait conditions (Table 3.7). The highest odds 
ratio was for speed while counting backwards (OR=3.73; 95% CI=2.22-6.26; p<0.001), 
while the lowest was for usual gait speed (OR=1.70; 95% CI=1.04-2.76; p=0.034). 
Naming animals and serial sevens were both in between these [NA(OR=2.73; 95% 




Figure 3.5 Receiver-operating characteristic (ROC) curves for gait speed’s ability to 
separate dementia from SCI and MCI patients in each gait condition 
 
 
Table 3.6 Gait speed cut-off values and associated sensitivity, specificity, and area 


























































Table 3.7 Association between slow gait speed on each test condition and dementia 
diagnosis 
Gait Condition Odds Ratio (95% CI) p-value 












Serial sevens 1.97 (1.06-3.68) 
 
0.03 































3.1.7 Feasibility Measures 
There were four hundred sixty-seven clinic visits marked as eligible during the study 
period. Of these, forty-three charts were missing from the clinic at the time of data 
collection. The total number of charts accessed was four hundred twenty-four. Fifty-two 
participants were excluded from data collection for reasons summarized in Table 3.8. The 
most common reason gait testing was not done was due to barriers of the participants 
(59.6%), including communication issues (28.8%) and being unable to ambulate the path 
freely (23.1%). Assessor issues accounted for 13.5% of those participants who could not 
be included. The final study sample (n=372) represents 87.7% of the total potential 
participants who had data available, showing that gait testing can be successfully 
performed in a large majority of clinic patients. 
Results from the feasibility survey of the assessors who completed the dual-task gait 
testing in the clinic are summarized in Table 3.9. Overall, both the physician and nurse 
clinician said that gait testing was “pretty easy” or 2 on a 5-point Likert scale for both 
ease of completing the test and ease of integrating it into the clinic visit. The additional 
comments made suggested that the gait collection form (see Appendix C), physical space 
to perform the test, and the timing of the appointment were all important aspects to 










Table 3.8 Reasons for exclusion from study for patients with an eligible clinic visit 
and available data 
Reason for Exclusion n % 
Participant issues 
     Using gait aid/unable to walk 
     Communication issues/language barrier 
     Refused 












     No trained assessor available 








     Under age limit (50 years old) 


















Table 3.9 Assessor feedback on feasibility of the dual-task gait assessment 
Assessor’s Position 
Ease of completing the 
assessment 
Ease of integrating 
the assessment into 






2 - “pretty easy” 2 - “pretty easy”  
Nurse Clinician 2 - “pretty easy” 2 - “pretty easy” “is relatively easy to 
complete with the 
template form” 
“Space in an office 
setting may be a limiting 
factor” 
“Sometimes it’s a 
challenge… depending 
upon how [early] patients 
arrive/ [how busy it is at] 
time of arrival” 




Chapter 4  
4 Longitudinal Analysis 
Poor gait performance, as indicated by slow gait speed and high dual-task cost, has been 
associated with future risk of falls and cognitive decline [15,106]. As gait testing can be a 
cost effective and easy to measure clinical marker, it may act as a complement to current 
cognitive assessments to detect those at high risk for future cognitive decline. This 
chapter will explore the relationship between poor gait performance at baseline and 
cognitive status at the next clinical follow-up at least one year later. The three outcome 
variables explored for cognitive status at follow-up visit are 1) progression to a more 
severe diagnosis, which was categorized as conversion from SCI to MCI or dementia, 
MCI to dementia, or early/prodromal dementia to moderate or severe dementia 2) global 
cognitive decline of >2 points per year on the MoCA and 3) global cognitive decline of 
>2 points per year on the MMSE. 
4.1 Results 
4.1.1 Participant Characteristics 
One hundred and seven patients met baseline inclusion criteria and had a second clinic 
visit at least twelve months later but still within the study period. Of these, nineteen had a 
baseline diagnosis of SCI, fifty-one had a baseline diagnosis of MCI, and thirty-seven 
had a baseline diagnosis of dementia.  Sixty-one participants had progressed to a more 
severe diagnosis at their follow-up visit, while forty-six participants had remained stable 
or improved at follow-up. Characteristics of the study sample stratified by diagnosis 
change status are shown in Table 4.1. Participants who progressed in diagnosis and those 
who were stable were statistically similar in all baseline variables. 
Characteristics of the study sample stratified by decline on cognitive testing are shown in 
Table 4.2 and Table 4.3. Twenty-nine participants showed significant decline in MoCA 
performance at follow-up (>2 points per year). Fifteen participants were missing MoCA 
score at one or both visits and therefore decline could not be calculated. Participants who 
showed significant decline on the MoCA and those who did not were statistically similar 
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in all baseline variables. Thirty participants showed significant decline on MMSE (>2 
points per year). Participants who showed decline on MMSE testing were significantly 





















Table 4.1 Baseline demographic and clinical characteristics of study participants in 
sample stratified by follow-up diagnosis status 
  Stratified by Diagnosis Status  









Age (mean, SD) 73.11 (9.47) 71.46 (10.60) 74.25 (8.43) 0.17a 
Female (n, %) 57 (53.3%) 27 (58.7%) 30 (49.2%) 0.33 
Years of education 
(mean, SD) 




5.94 (2.99) 6.39 (2.71) 5.60 (3.15) 0.18 
No. of medications 
(mean, SD) 
8.28 (3.86) 8.56 (4.34) 8.06 (3.48) 0.52a 
MMSE score 
(mean, SD) 
25.76 (4.01) 26.57 (3.71) 25.15 (4.16) 0.07 
MoCA score 
(mean, SD) 
20.76 (5.18)e 21.76 (4.95)f 19.98 (5.25)g 0.08 
Baseline diagnosis 
(n, %) 
    
     SCI 19 (17.8%) 10 (21.7%) 9 (14.8%) 0.57 
     MCI 51 (47.6%) 22 (47.8%) 29 (47.5%) 
     Dementia 37 (34.6%) 14 (30.4%) 23 (37.7%) 
Statistically significant values are bolded. 
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment. 
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment. 
a, p-value reported from Welch’s Test for unequal variance. 
b, data available for n=99. 
c, data available for n=44. 
d, data available for n=55. 
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e, data available for n=103. 
f, data available for n=45. 



















Table 4.2 Baseline demographic and clinical characteristics of study participants in 
sample stratified by follow-up MoCA change status 
  Stratified by MoCA score change  
Variable Total Cohort 
(n=92) 







Age (mean, SD) 72.54 (9.54) 71.76 (10.22) 74.24 (7.75) 0.20a 












8.46 (3.98) 8.68 (4.45) 7.96 (2.68) 0.34a 
MMSE score 
(mean, SD) 
26.55 (3.40) 26.60 (3.84) 26.45 (2.23) 0.84 
MoCA score 
(mean, SD) 
21.34 (5.04) 21.16 (5.33) 21.72 (4.40) 0.62 
Baseline 
diagnosis (n, %) 
    
     SCI 19 (20.6%) 14 (22.2%) 5 (17.2%) 0.86 
     MCI 45 (48.9%) 30 (47.6%) 15 (51.7%) 
     Dementia 28 (30.4%) 19 (30.2%) 9 (31.0%) 
Statistically significant values are bolded. 
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment. 
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment. 
a, p-value reported from Welch’s Test for unequal variance. 
b, data available for n=86. 
c, data available for n=60. 
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Table 4.3 Baseline demographic and clinical characteristics of study participants in 
sample stratified by follow-up MMSE change status 
  Stratified by MMSE score change  
Variable Total Cohort 
(n=107) 







Age (mean, SD) 73.11 (9.47) 71.99 (9.78) 76.00 (8.09) 0.048 












8.28 (3.86) 8.45 (4.10) 7.83 (3.18) 0.41a 
MMSE score 
(mean, SD) 
25.76 (4.02) 26.44 (3.74) 24.00 (4.22) 0.004 
MoCA score 
(mean, SD) 
20.76 (5.18)e 21.92 (5.08)f 17.48 (3.97)g <0.001 
Baseline 
diagnosis (n, %) 
    
     SCI 19 (17.8%) 19 (24.7%) 0 (0.0%) 0.003 
     MCI 51 (47.6%) 37 (48.0%) 14 (46.7%) 
     Dementia 37 (34.6%) 21(27.3%) 16 (53.3%) 
Statistically significant values are bolded. 
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment. 
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment. 
a, p-value reported from Welch’s Test for unequal variance. 
b, data available for n=99. 
c, data available for n=74. 
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d, data available for n=25. 
e, data available for n=103. 
f, data available for n=76. 


















4.1.2 Gait Performance and Association with Progression in Cognitive 
Diagnosis 
Table 4.4 reports the association between progression in cognitive diagnosis and gait 
speed and DTC as continuous variables as determined by the cox regression models. 
Only performance on the naming animals dual-task test was significantly associated with 
future decline in cognitive diagnosis. Both gait speed (presented as 1/exp(B): HR=1.02; 
95% CI=1.00-1.03; p=0.004) and DTC (HR=1.02; 95% CI=1.01-1.04; p=0.011) in the 
naming animals condition were associated with diagnosis progression. These associations 
remained significant when adjusted for age, sex, and comorbidities. Performance in usual 
gait speed and the other dual-tasks were not significantly associated with the outcome 
variable. 
Modeling gait speed and DTC as dichotomous variables using a mean split showed that 
only slow gait speed on the naming animals dual-task condition was associated with 
diagnosis progression (HR=1.73; 95% CI=1.03-2.91; p=0.037) (Table 4.5). This 












Table 4.4 Cox proportional hazard regression of the association of continuous gait 
speed and dual-task cost with cognitive diagnosis progression 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual 1.01 (0.99-1.02) 0.31 1.00 (0.99-1.01) 0.80 
Counting backwards 1.01 (1.00-1.02) 0.08 1.01 (1.00-1.02) 0.14 
Naming animals 1.02 (1.00-1.03) 0.004 1.02 (1.00-1.03) 0.01 
Serial sevens 1.01 (0.99-1.02) 0.38 1.00 (0.99-1.02) 0.55 
Dual-Task Cost  
    
Counting Backwards 1.01 (0.99-1.02) 0.39 1.01 (1.00-1.03) 0.15 
Naming animals 1.02 (1.01-1.04) 0.01 1.02 (1.01-1.04) 0.008 
Serial sevens 1.00 (0.98-1.02) 0.88 1.01 (0.99-1.02) 0.61 
Statistically significant values are bolded. 
Abbreviations: HR = Hazard ratio. 
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.  







Table 4.5 Cox proportional hazard regression of the association of dichotomous gait 
speed and dual-task cost with cognitive diagnosis change 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual (<102.6cm/s) 1.26 (0.76-2.09) 0.38 1.12 (0.65-1.93) 0.68 
Counting backwards 
(<81.6cm/s) 
1.05 (0.63-1.77) 0.84 1.15 (0.68-1.96) 0.60 
Naming animals 
(<75.1cm/s) 
1.73 (1.03-2.91) 0.04 1.60 (0.94-2.72) 0.09 
 Serial sevens 
(<60.7cm/s) 
1.22 (0.69-2.16) 0.49 1.07 (0.60-1.94) 0.81 
Dual-Task Cost  
    
Counting Backwards 
(>21.1%) 
1.19 (0.71-2.00) 0.51 1.45 (0.85-2.49) 0.17 
Naming animals 
(>27.0%) 
1.50 (0.90-2.50) 0.12 1.57 (0.97-2.63) 0.09 
Serial sevens (>41.0%) 1.15 (0.65-2.00) 0.62 1.28 (0.72-2.29) 0.40 
Statistically significant values are bolded. 
Abbreviations: HR = Hazard ratio. 







4.1.3 Gait Performance and Association with Decline on the Montreal 
Cognitive Assessment (MoCA) 
Table 4.6 shows the association between continuous gait variables and decline on the 
Montreal Cognitive Assessment (MoCA). Higher DTC in the naming animals condition 
was significantly associated with decline on the MoCA (HR=1.03; 95% CI=1.00-1.05; 
p=0.027). This association remained significant when adjusted for age, sex, and 
comorbidities. No other gait variables showed a significant association with decline on 
the MoCA.  
When modeled as dichotomous variables, none of the gait variables were significantly 















Table 4.6 Cox proportional hazard regression of the association of continuous gait 
speed and dual-task cost with MoCA score decline 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual 1.00 (0.98-1.02) 0.99 0.99 (0.97-1.01) 0.31 
Counting backwards 1.01 (1.00-1.03) 0.18 1.01 (0.99-1.02) 0.43 
Naming animals 1.01 (1.00-1.03) 0.08 1.01 (0.99-1.03) 0.25 
Serial sevens 1.01 (0.99-1.03) 0.24 1.01 (0.99-1.03) 0.56 
Dual-Task Cost  
    
Counting Backwards 1.02 (0.99-1.04) 0.16 1.02 (1.00-1.04) 0.13 
Naming animals 1.03 (1.00-1.05) 0.03 1.02 (1.00-1.05) 0.03 
Serial sevens 1.02 (0.99-1.04) 0.22 1.01 (0.99-1.04) 0.27 
Statistically significant values are bolded. 
Abbreviations: MoCA= Montreal Cognitive Assessment. HR = Hazard ratio. 
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.  







Table 4.7 Cox proportional hazard regression of the association of dichotomous gait 
speed and dual-task cost with MoCA score decline 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual (<102.6cm/s) 1.21 (0.58-2.51) 0.61 0.98 (0.44-2.15) 0.95 
Counting backwards 
(<81.6cm/s) 
1.35 (0.64-2.83) 0.43 1.32 (0.60-2.90) 0.49 
Naming animals 
(<75.1cm/s) 
1.71 (0.82-3.59) 0.15 1.56 (0.72-3.36) 0.26 
 Serial sevens 
(<60.7cm/s) 
2.16 (0.93-5.01) 0.08 1.72 (0.71-4.16) 0.23 
Dual-Task Cost  
    
Counting Backwards 
(>21.1%) 
1.54 (0.74-3.20) 0.24 1.67 (0.79-3.55) 0.18 
Naming animals 
(>27.0%) 
1.65 (0.79-3.43) 0.18 1.71 (0.82-3.59) 0.16 
Serial sevens (>41.0%) 1.77 (0.78-4.00) 0.17 1.76 (0.74-4.15) 0.20 
Statistically significant values are bolded. 
Abbreviations: MoCA= Montreal Cognitive Assessment. HR = Hazard ratio. 







4.1.4 Gait Performance and Association with Decline on the Mini Mental 
State Exam (MMSE) 
Table 4.8 shows the association between continuous gait variables and decline on the 
Mini Mental State Exam (MMSE). Slower gait speed in the naming animals condition 
was significantly associated with decline on the MMSE (presented as 1/exp(B): 
HR=1.02; 95% CI=1.00-1.04; p=0.01). This association remained significant when 
adjusted for age, sex, and comorbidities. No other gait variables showed a significant 
association with decline on the MoCA.  
When modeled as dichotomous variables, none of the gait variables were significantly 















Table 4.8 Cox proportional hazard regression of the association of continuous gait 
speed and dual-task cost with MMSE score decline 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual 1.01 (1.00-1.03) 0.16  1.01 (0.99-1.02) 0.48 
Counting backwards 1.01 (0.99-1.03) 0.20 1.01 (0.99-1.02) 0.43 
Naming animals 1.02 (1.00-1.04) 0.01 1.02 (1.00-1.04) 0.04 
Serial sevens 1.02 (0.99-1.04) 0.15 1.01 (0.99-1.03) 0.38 
Dual-Task Cost  
    
Counting Backwards 1.00 (0.98-1.03) 0.78 1.01 (0.98-1.03) 0.59 
Naming animals 1.02 (1.00-1.05) 0.08 1.02 (1.00-1.05) 0.07 
Serial sevens 1.00 (0.98-1.03) 0.87 1.01 (0.98-1.03) 0.68 
Statistically significant values are bolded. 
Abbreviations: MMSE = Mini Mental State Exam. HR = Hazard ratio. 
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.  







Table 4.9 Cox proportional hazard regression of the association of dichotomous gait 
speed and dual-task cost with MMSE score decline 
Variable 
Model 1 (Unadjusted) Model 2 (Adjusted) 
HR (95% CI) p-value HR (95% CI) p-value 
Speed  
    
Usual (<102.6cm/s) 1.32 (0.64-2.71) 0.45 1.12 (0.52-2.42) 0.76 
Counting backwards 
(<81.6cm/s) 
1.06 (0.50-2.23) 0.87 1.08 (0.50-2.33) 0.84 
Naming animals 
(<75.1cm/s) 
1.76 (0.84-3.72) 0.14 1.55 (0.72-3.33) 0.26 
 Serial sevens 
(<60.7cm/s) 
2.21 (0.91-5.39) 0.08 1.64 (0.65-4.18) 0.23 
Dual-Task Cost  
    
Counting Backwards 
(>21.1%) 
 0.78 (0.36-1.69) 0.53  0.88 (0.40-1.95) 0.75 
Naming animals 
(>27.0%) 
1.47 (0.71-3.05) 0.30 1.62 (0.77-3.40) 0.20 
Serial sevens (>41.0%) 1.32 (0.58-3.00) 0.51 1.49 (0.64-3.44) 0.35 
Statistically significant values are bolded. 
Abbreviations: MMSE = Mini Mental State Exam. HR = Hazard ratio. 







4.1.5 Data Attrition Measures 
As only about a quarter of the original sample (n=107) was included in the longitudinal 
analysis, it was also investigated why those who were not included did not have a second 
visit within the study period. A summary of these findings is presented in Table 4.10.  
The most common reasons for not being included in longitudinal analysis were related to 
study criteria (n=134). One hundred and seventeen patients had a follow-up visit 
scheduled, but it landed outside of the approved period of data collection, which ended in 
June 2019. Sixteen patients had a second visit at the clinic that was less than twelve 
months after their first. These were mostly consults and did not often include any new 
testing. One patient was not able to be included in analysis as they were not able to 
verbally communicate at the follow-up visit. 
Thirty-four patients did not have any further follow-up scheduled in the Aging Brain and 
Memory clinic. Thirty-two of these patients were referred to another service or 
department for follow-up. Two of these patients were discharged at their baseline visit, as 
they did not wish to be followed in the clinic. 
Twenty-four patients were lost to follow-up. These included ten cancellations and twelve 
patients who did not show-up for their appointments. Additionally, one patient 
rescheduled their visit to after June 2019, making it no longer eligible, and one patient 
moved out of the province. 
No data was available for seventy-three patients at the time of data collection for follow-
up visits. 
Table 4.11 shows the comparison of baseline clinical and demographic characteristics 
between those who were included in the longitudinal study (had a follow-up visit) and 
those who weren’t. The two groups were statistically similar in all characteristics, except 
MMSE score (p=0.008). However, the mean score for each of the two groups were less 
than one point apart, so this is likely not a clinically significant difference. 
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Table 4.10 Reasons for exclusion from longitudinal analysis for patients without a 
second clinic visit 
Reason for Exclusion n % 
Lost to follow-up 
     Cancelled  
     No show  
     Rescheduled out of study period (after June 2019) 











No follow-up scheduled 
     Referred to another servicea 








     Next visit after study end date (June 2019) 
     Next visit less than 12 months from baseline 









No data available 73 19.6 
Percentage value is in comparison to total cohort. 
Total cohort size n=372. Longitudinal analysis n=107. 
a, these included neuropsychology, long-term care, psychiatry, research, and other clinics 
(due to geographic location). 








Table 4.11 Baseline demographic and clinical characteristics of study participants 
stratified by inclusion in longitudinal study 
Variable Included (had 
follow-up visit) 
(n=107) 




Age (mean, SD) 73.11 (9.47) 72.81 (10.32) 0.18 
Female (n, %) 57 (53.3%) 132 (49.8%) 0.58 
Years of education (mean, 
SD) 
12.80 (3.01)a 12.59 (3.60)b 0.18 
No. of Comorbidities 
(mean, SD) 
5.94 (2.99) 5.49 (3.34) 0.93 
No. of medications (mean, 
SD) 
8.28 (3.86) 8.58 (3.40) 0.54 
MMSE score (mean, SD) 25.76 (4.02) 25.12 (4.88)c 0.008 
MoCA score (mean, SD) 20.76 (5.18)d 21.31 (4.98)e 0.74 
Baseline diagnosis (n, %)    
     SCI 19 (17.8%) 62 (23.4%) 0.30 
     MCI 51 (47.6%) 104 (39.2%) 
     Dementia 37 (34.6%) 99 (37.4%) 
Statistically significant values are bolded. 
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment. 
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment. 
a, data available for n=99. 
b, data available for n=233. 
c, data available for n=263. 
d, data available for n=103. 




Chapter 5  
5 General Discussion and Conclusions 
5.1 Discussion 
This thesis aimed to assess dual-task gait performance in a memory clinic setting across 
the spectrum of cognitive impairment diagnoses. It was hypothesized that slow gait speed 
and high dual-task cost would be associated with a more severe baseline cognitive 
diagnosis, and would be associated with accelerated cognitive decline at a follow-up visit. 
Our results showed that slow usual gait speed and slow gait speed while dual-tasking was 
associated with a diagnosis of dementia at baseline. Also, dual-task gait testing was able 
to be completed with almost 88% of eligible participants over a four year period, 
demonstrating that gait testing is feasible to perform in clinics. In our longitudinal 
analysis, there was a signal that poor dual-task gait performance at baseline, specifically 
in the naming animals task, may be associated with cognitive decline at the follow-up 
visit. 
5.1.1 Cross-Sectional Gait Performance 
Our results show that gait speed decreases across the spectrum of cognitive impairments, 
confirming in a clinical setting the relationship between gait and cognition that has been 
seen is other studies [132]. Gait speed was significantly different both across diagnosis 
groups and between different dual-tasks with each group. Interestingly, in all four dual-
task conditions the SCI and MCI groups had statically similar performance. This means 
the SCI group had normal scores on tests of global cognition [133,134], but performed 
similar in the dual-task test to the MCI group, who have objective cognitive impairments. 
As we know patients with SCI are at increased risk for future cognitive decline [41], it is 
possible the dual-task test is able to detect these early subtle changes in cognition that 
cannot yet be seen on global cognitive testing. For example, the level of stress put on the 
brain as a result of the dual-task gait test may be more than or target different resources 
than traditional cognitive tests, and is therefore able to detect deficits at even the earliest 
stage. Further studies using a healthy control group with no cognitive complaints and a 
longer follow-up period would be needed to confirm this theory. 
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All groups had a mean usual gait speed of over 80 cm/s, with the SCI group at 111 cm/s, 
the MCI group at 106 cm/s, the dementia group at 91 cm/s, and 102cm/s as the mean for 
the whole cohort. Eighty cm/s is considered to be the cut-off for slow gait speed in 
association with gait pathologies and falls risk [70]. This means our sample had moderate 
to high mobility function [88,117], and using this cut-off alone would not have been 
sufficient to detect differences across the cognitive impairment groups. While mean gait 
speed for the dementia group was still above 80 cm/s, the difference in mean gait speed 
from the SCI and MCI groups was >10 cm/s, which is considered clinically meaningful 
[135]. 
While the exact neural mechanisms behind the dual-task paradigm are not yet 
understood, it is thought that both gait and cognitive tasks compete for a limited amount 
of resources in overlapping brain regions. This is supported by imaging studies that have 
shown higher activation in prefrontal brain regions when imagining walking while 
talking versus just walking [105]. Alternatively, damage or atrophy in these shared brain 
areas also causes detriments in both gait and cognition [103,104,136,137]. Our results are 
in line with this theory, as those with more severe cognitive diagnoses had slower gait 
speed, both in usual gait speed and while dual-tasking. Future neuroimaging studies 
would be needed to expand on this theory. 
Interestingly, dual-task gait cost was not significantly different between the diagnosis 
groups. This goes against our original hypothesis and several other studies [96,132,138]. 
However, in the counting backwards and naming animals tasks, dual-task gait cost did 
increase slightly across the groups as we hypothesized, although when using all four gait 
tests together and excluding missing data this was not significant due to a power issue. 
Due to our statistical analysis design and the clinical nature of our study, we had to 
exclude a large number of participants from this analysis as they refused one or more of 
the dual-task conditions. It is possible that those who refused one of the tasks had a 
higher level of cognitive impairment and were embarrassed or fearful of attempting the 
task. This would lead to the mean DTC in these groups being lower than it truly would be 
if all participants had attempted the task. DTC did increase within each diagnosis group 
with increasing task difficulty, as has been shown in previous studies [118]. 
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Regression analysis showed that slow gait speed and high dual-task cost were 
significantly associated with diagnosis of dementia. Receiver operating characteristic 
(ROC) curve analysis also showed that gait speed on each of the four gait tasks was low 
to moderate, with area under the curve (AUC) ranging from .657 to .711. Sensitivity and 
specificity for dementia diagnosis were also moderate, ranging from 62.8%-72.3% and 
60.0%-64.9%, respectively. In comparison, the gold standard tests for cognitive 
impairment, the MoCA and MMSE, were found to have sensitivity of 83% and 72% and 
specificity of 86% and 83%, respectively, for predicting dementia [139]. While dual-task 
gait testing is not as strong as these tests alone, it can be used in conjunction with these 
traditional assessments as a quick and easy measure of the cognitive-motor interaction, 
which these tests cannot measure, and to improve diagnosis and treatment plans for 
patients. For example, a high dual-task gait cost may inform clinicians to send a patient 
for more in depth neuropsychological evaluation or for brain imaging, which may catch 
deficits at an earlier stage or give insight to the cause of these deficits. 
Finally, our study has shown that dual-task gait testing is feasible to perform in a clinical 
setting. Eighty-eight percent of eligible patients completed at least part of the gait testing 
and could be included in analysis. A recent study of gait testing in an outpatient 
neurology clinic had a similar rate of test completion (81%) [140]. This, in addition to 
other studies done in a memory clinic setting [95,96], shows that dual-task gait testing 
can be done even in busy clinic settings. Both assessors reported the testing was “pretty 
easy” to complete and to add into the clinic visit. Some important tips for integration 
were presented, including the use of a standard collection form and the requirement of 
physical space. The methodology used here is quick, cost-effective, and requires minimal 
equipment to be completed. While our results have shown some differences in sensitivity 
and specificity between the different dual-tasks, it is still recommended to complete all 
three tests. Even in a busy clinical setting, it usually takes under five minutes to complete 
all four walks together, and it has been shown that the different cognitive tasks are 
needed as they assess different domains of cognition and may together create the optimal 
level of difficulty for all patients [141]. 
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5.1.2 Longitudinal Gait Performance  
While the previous sub-study answered our research questions regarding feasibility and 
practicality of gait testing and differences between diagnosis groups, there was still a gap 
in the literature of a longitudinal study of gait testing across the cognitive spectrum in a 
memory clinic cohort. Therefore, we decided to perform longitudinal analysis for any 
participants who had a second clinic visit during the study period. It was hypothesized 
that slow gait speed and greater dual-task gait cost at baseline would be predictive of 
cognitive decline at the follow-up visit. Previous research has shown that dual-task gait 
cost was a predictor of progression from MCI to dementia [15], however the limited 
studies of dual-task gait testing in a clinical setting have not shown the same results [96]. 
Our results show a signal that dual-task performance in the naming animals condition 
may be associated with change in diagnosis, which was a composite outcome including 
change from SCI to MCI, MCI to dementia, and early to late dementia. Both continuous 
gait speed and dual-task cost were associated with diagnosis change, even when adjusted 
for covariates. Dichotomous slow gait speed (using a median split) while naming animals 
was also associated with decline in diagnosis, although this association was not robust to 
adjustment for confounders. Several past studies have also found usual gait speed to have 
a weaker association with cognitive status and future cognitive decline [15,132,142,143]. 
However, differential associations between the dual-task conditions has not been 
thoroughly examined previously. It is possible that because the naming animals condition 
relies more purely on recall and semantic memory [144], while the arithmetic tasks rely 
on executive functions [145], that the naming animals task was most sensitive to changes 
as clinic patients were often being assessed for memory complaints. Alternatively, it is 
also possible that the naming animals task provides the optimal level of difficulty while 
also keeping patients’ mental engagement (ie. not “giving up”). Naming animals is also a 
more universal task for a wide range of patients, as it has less influence from education 
level [146]. Additional cognitive testing to determine which cognitive domains are 
impaired in our cohort would be needed to examine this further. 
Additionally, the association between poor gait performance at baseline and decline on 
cognitive testing was examined. It was found that again, the only condition to show a 
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signal of association was the naming animals task. Continuous dual-task cost while 
naming animals was significantly associated with decline of >2 points per year on the 
Montreal Cognitive Assessment (MoCA). Continuous slow gait speed while naming 
animals was associated with decline of >2 points per year on the Mini Mental State Exam 
(MMSE). Both of these associations remained significant even when adjusted for 
covariates. Similarly to the previous result, it is possible that the differential domains and 
pathways used in these dual-tasks could explain why only the naming animals dual-task 
shows a signal of association. Also, because the MoCA and MMSE are both measures of 
global cognitive function and not any domain specifically, it is possible that cognitive 
tests tailored to one specific cognitive domain would show a higher association with gait 
performance, especially in subtypes of each cognitive diagnosis. 
While only 28.8% of participants could be included in longitudinal analysis, only 6.5% of 
participants were confirmed lost to follow-up. Thirty six percent of participants could not 
be included as their second visit to the clinic fell outside of the time range of the study. 
Nine percent (9.1%) of patients were not scheduled to be followed in the clinic for 
reasons not related to the study, and 19.6% of patients were not able to be included in 
follow-up analyses due to missing data. As the largest proportion of patients were 
excluded due to time constraints, both directly by the study design and indirectly by the 
scheduling constraints in a busy clinic, the study follow-up period should be extended in 
future studies to better capture the entire study sample. Still, even if we assume all 
patients who could not be included due inaccessible data were lost to follow-up, we only 
had an annual dropout rate of 6.5% of patients, which is comparable to other large 
observational memory clinic studies [147,148]. 
5.1.3 Strengths 
This study is the largest investigation of dual-task gait testing in clinical patients to date, 
and includes all three common diagnosis groups. This demonstrates the feasibility of 
performing dual-task gait testing in a busy clinical setting, as a high percentage of total 
patients completed the assessment. Also, this thesis presents both cross-sectional and 
longitudinal analyses of gait and cognitive performance. Finally, we used previously 
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published gait testing guidelines [14], which will make comparison of our data to other 
large cohorts possible. 
5.1.4 Limitations 
Our analyses also have several limitations that we acknowledge. Firstly, using limited 
exclusion criteria allowed us to sample a large majority of the clinic population, but could 
lead to increased heterogeneity in each diagnosis group. Subtypes of MCI and dementia 
were grouped together, which may have implications on the relationship between gait 
performance and cognitive outcomes. For example, it has been shown in the past that 
dual-task gait testing may better predict conversion to vascular dementia than 
Alzheimer’s disease [149]. The associations found in this current study may be 
influenced by strong associations within one subtype, even with weaker associations or 
no association at all possible in other subtypes. Our statistical analysis design for cross-
sectional comparisons of gait speed and DTC required that any patients who did not 
complete all three dual-task be excluded from analysis. This could affect external 
validity, as participants who refused one or more tasks could actually have worse 
cognitive or mobility impairments than could be represented in the presented data. If 
those excluded had worse performance on the other remaining dual-tasks the mean dual-
task cost in these tasks is actually under-estimated in this sample and between group 
differences may actually be larger than estimated here within. Additionally, we focused 
on dual-task gait cost only, but adding dual-task cognitive cost to our methodology would 
have improved our understanding of the dual-task paradigm in this sample. Information 
on education level of patients was collected but was not used as a covariate in analyses, 
which may impact the associations shown as education has a protective role in cognitive 
function and decline. Finally, our study was only completed at one hospital based clinic 
site in London, Ontario with a supervising team of one physician and one nurse clinician, 
which may limit it’s generalizability to other clinic. 
5.1.5 Future Directions 
While our results fill in some of the current gaps in this area of literature, there are many 
other research questions that still need to be addressed. Firstly, while we explored 
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feasibility, sensitivity, and specificity of dual-task gait testing, it still needs to be 
determined how this test could be useful in clinical practice and how it would fit with the 
current gold standards of assessment. With the new results from this thesis, we have 
shown that dual-task gait testing is associated with cognitive impairments in a clinical 
setting, but how this could aid in differential diagnosis and treatment plans is still unclear. 
Previously, we have published instructions to easily perform gait testing in clinics and 
created videos to aid in the training of clinicians in this form of testing (see Appendix D). 
This will assist greatly to facilitate the dissemination of this testing to additional clinic 
sites and to allow the use of this testing to be further studied in other clinical settings. 
Our results have shown a signal that dual-task performance at baseline may be associated 
with future cognitive outcomes. However, larger studies with more homogenous samples 
would be needed to further explore this relationship. For example, how this relationship 
manifests in SCI to MCI, MCI to dementia, and early to late stage dementia transitions 
should all be explored independently. They have unique factors that may influence the 
how this association is expressed and how it can be applied in clinical diagnoses and 
treatments. 
Studies with a longer follow-up period may also show a stronger association between 
baseline gait performance and cognitive decline. The follow-up period for our study 
ranged from approximately one to three years. While some studies have found 
meaningful changes in cognition in a similar time span [150], some studies report the 
mean time needed to see clinically relevant symptoms may be more than twice as long as 
this [151,152]. Therefore, the follow-up period of our study may have been too short to 
capture the full picture of cognitive decline in our sample. Extending this follow-up 
period in the future may show a stronger relationship between gait performance and 
cognitive outcomes in a clinical setting. 
5.2 Conclusions 
This thesis has examined gait performance, specifically when dual-tasking, in a large 
cohort of memory clinic patients, both cross-sectionally and longitudinally. Our result 
show that gait speed and dual-task performance decline across the cognitive spectrum. 
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Motor performance testing was feasible to perform in a real clinical scenario and results 
were collected with minimal missing data. Additionally, we found a strong signal that 
results from this testing can help to differentiate between cognitive diagnoses across the 
spectrum of cognitive impairments seen in clinical settings. Our longitudinal analysis 
showed that poor dual-task performance may be an indicator of risk of future cognitive 
decline, however a larger sample with the opportunity to analyze each diagnosis group 
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Appendix D: Byproducts of this Thesis and Links to Media 
 
The following instructional video is included as a byproduct to this thesis. It outlines 
instructions for how gait assessments are to be performed and recorded in a clinical 
setting. This video was produced and edited by myself (Stephanie Cullen) and Manuel 
Montero-Odasso with the help of the Gait and Brain Lab team. 
Link: https://www.youtube.com/watch?v=DVAEENexaac&feature=emb_title 
 
During my Masters, I also recreated our lab website with many online resources for 
researchers and for patients who would like to learn more about gait testing and mobility. 
These can be found at www.gaitandbrain.com.  
 
More details about my research productivity and outputs during my Masters can be found 
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